Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental ...

Roche RHHBY announced that the FDA has accepted and granted priority review to its supplemental biologics license application ...

The FDA granted priority review to a supplemental biologics license application for Enspryng for thyroid eye disease, ...

Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.

Priority review positions satralizumab as a potentially practice-shifting alternative to IV IGF-1R inhibitors, primarily differentiated by subcutaneous self-administration and at-home dosing. Two ...

Lumvoa (veligrotug-vvze) is now FDA-approved to treat thyroid eye disease regardless of activity or duration, offering a new therapeutic option for both active and chronic phases. The Food and Drug ...

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.’s VRDN new thyroid eye disease (TED) ...

FDA labeling covers active and chronic TED, addressing a major evidentiary gap left by prior IGF-1R inhibition programs that primarily enrolled active disease populations. Two pivotal phase 3 trials ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today ...

A new study suggests women with longer reproductive lifespans and those who take hormone therapy may have a higher risk of thyroid cancer. This effect was even stronger in women who used hormone ...

ABSTRACT: Differentiated thyroid cancer represents the most common pathological type of thyroid malignancy, for which postoperative radioiodine therapy serves as a crucial adjuvant treatment modality.

ABSTRACT: We describe a female patient with a history of antiphospholipid syndrome, hypothyroidism, and bipolar disorder, who presented with worsening mood and psychotic symptoms following ...